What is the breakup of the 90-molecule pipeline across Agchem, Electronics, Pharma, and Biologicals?

The pipeline is a funnel approach with majority in Agchem; NCE pipeline, biologicals, electronics all contribute, but a detailed breakup is not shared. Each segment shows positive trajectory.

Can you quantify the pharma order book delay and maintain pharma business guidance?

CRDMO business sees sequential delays but revenue gets securitized; early stage means higher volatility, but as portfolio scales, standard deviation reduces. Guidance maintained unless there are shifts.

What are the peak sales expectations for the new foliar nematode nematicide?

Performance is extremely successful; we will share potential after field validation. We do not chase anything less than three digits in millions of dollars.

Why is there a disconnect between rupee depreciation benefit and export value decline?

PI follows a pass-through model with currency risk management; currency benefits are shared with partners, and the business focuses on product margins, not currency gains.

When will the global biologics and pharma subsidiary losses break even?

Investments in biologics are for market development and demonstrations, which are front-loaded; these are 'good losses' to build future revenue. R&D spending is never a loss but value creation. We will try to share quarterly biologics details separately.

P I Industries Q1 FY27 Earnings Call — Analysis (NSE: PIIND)

PI Industries navigates Q1FY27 headwinds with domestic volume growth and biologic traction, while guiding for gradual recovery led by new launches and exports recovery.

18 Aug 2026 · Analysis by Alpha Inflection

Result quality: poor — Revenue declined. Management sentiment: cautious.

The take

Q1FY27 Revenue ₹1,702.3 Cr .

Results

Revenue ₹1,702.3 Cr, gross margin 57%, EBITDA margin 22%; domestic agri volume up 12% driven by biologicals, exports volume down 8%, net cash ₹3,800 Cr, working capital reduced by 19 days releasing ₹300 Cr.

Financial highlights

P I Industries Q1 FY27 reported figures
Metric	Value	Basis
Revenue	₹1,702.3 Cr	none · Q1FY27
Gross Margin	57%	point_in_time · Q1FY27 · Q1FY27
EBITDA	₹369.3 Cr	none · Q1FY27
EBITDA Margin	22%	point_in_time · Q1FY27 · Q1FY27
Order Book	$1.2 billion	sequential · Jun-26 · stable sequentially
Contract Assets	₹750 Cr	point_in_time · Jun-26 · as of June 2026
Net Cash	₹3,800 Cr	point_in_time · Jun-26 · as of June 2026
Capex (Q1)	₹250 Cr	none · Q1FY27

Guidance

FY27 revenue growth guided in lower single digits, ETR ~24%, capex ₹700-800 Cr, with exports recovery expected in H2 and 4-5 new molecule launches across Agchem, Electronics, and Pharma.

Key themes

Cyclical headwinds meet new platform scaling

Operational commentary

Commissioned world’s largest flow plant with advanced flow chemistry capabilities, improving process control, safety, and cost efficiency.
First NCE insecticide Pioxaniliprole set for domestic launch within FY27 pending regulatory approval; international registrations planned for one geography in FY28 and another in FY29.
Dicloromezotiaz (new generation product for diamondback moth) to be launched this season in India.
4-5 new molecules targeted for launch in FY27 across Agchem, Electronics Chemicals, and Pharma.
Global biologicals platform: foliar nematode nematicide registered in Brazil, Mexico, US; 500+ field trials, 1,000+ grower engagements; unique foliar application differentiates from soil-applied chemicals.
Pharma CRDMO: integrated drug discovery partnership secured with a biotech; bandwidth for 2-3 more such deals; early-stage but building patient capital.
Electronic chemicals: commercial plant operational, supplies commenced; investing in next-gen high-tech manufacturing asset.
Net working capital reduced by 19 days, unlocking ₹300 Cr cash; debt-free balance sheet with net cash ₹3,800 Cr.
Domestic agri channel: >15,000 distributors, 1.5 lakh retailers; biologicals portfolio grew 50% YoY.

Analyst Q&A

Q. What is the breakup of the 90-molecule pipeline across Agchem, Electronics, Pharma, and Biologicals?
The pipeline is a funnel approach with majority in Agchem; NCE pipeline, biologicals, electronics all contribute, but a detailed breakup is not shared. Each segment shows positive trajectory.
Q. Can you quantify the pharma order book delay and maintain pharma business guidance?
CRDMO business sees sequential delays but revenue gets securitized; early stage means higher volatility, but as portfolio scales, standard deviation reduces. Guidance maintained unless there are shifts.
Q. What are the peak sales expectations for the new foliar nematode nematicide?
Performance is extremely successful; we will share potential after field validation. We do not chase anything less than three digits in millions of dollars.
Q. Why is there a disconnect between rupee depreciation benefit and export value decline?
PI follows a pass-through model with currency risk management; currency benefits are shared with partners, and the business focuses on product margins, not currency gains.
Q. When will the global biologics and pharma subsidiary losses break even?
Investments in biologics are for market development and demonstrations, which are front-loaded; these are 'good losses' to build future revenue. R&D spending is never a loss but value creation. We will try to share quarterly biologics details separately.

View source

Research and educational content only. Not investment advice.